Back to Results
First PageMeta Content
Juvéderm / Hyaluronan / ISO 10993 / Lidocaine / Sodium hyaluronate / Biocompatibility / Pre-clinical development / Sterilization / Medicine / Glycosaminoglycans / Plastic surgery


P110033 Executive Summary
Add to Reading List

Open Document

File Size: 549,59 KB

Share Result on Facebook

City

Goleta / /

Company

Table 9 Subgroup / Allergan / Ames / /

Country

France / /

Currency

pence / /

Event

FDA Phase / /

IndustryTerm

combination product / dermal filler product / dermal filler products / manufacturing process / /

MedicalCondition

preclinical irritation / previously conducted cancer / cancer / chronic toxicity study / potential cancer / repeat intracutaneous irritation / repeat irritation / macroscopic irritation / further irritation / irritation / acceptable cancer / short duration irritation / inflammation / calculated cancer / excess cancer / /

MedicalTreatment

Retreatment / Plastic and Reconstructive Surgery / /

Organization

Institutional Review Board / Food and Drug Administration / Center for Devices and Radiological Health / FDA / Extrusion Force / FDA’s Center for Drug Evaluation and Research / Division of Surgical Devices / FDA’s Center for Devices and Radiological Health / /

Position

PMA P110033 Executive Summary General / Treating Investigator / Executive / General / /

Product

Lidocaine / lidocaine hydrochloride / P110033 / XC / /

ProgrammingLanguage

DC / /

ProvinceOrState

Maryland / California / /

PublishedMedium

the FDA review / /

SocialTag